Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation

Pediatric Blood and Cancer

Volumn 55, Issue 6, 2010, Pages 1172-1179

  Elhasid, Ronit ^a,b   Krivoy, Norberto ^b,c   Rowe, Jacob M ^b,d   Sprecher, Eli ^b,e   Adler, Lior ^b   Elkin, Hela ^b   Efrati, Edna ^b  

^a MEYER CHILDREN S HOSPITAL   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Clinical Pharmacology Institute   (Israel)

^d Hematology Laboratory   (Israel)

^e TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Busulfan pharmacokinetics; Children; Glutathione S transferase genotyping; HSCT

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; HEPARIN; METHOTREXATE; THYMOCYTE ANTIBODY; URSODEOXYCHOLIC ACID;

ARAB; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MEGADOSE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HUMAN; JEW; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MOSLEM; MYCOSIS; MYELOABLATIVE CONDITIONING; NULL ALLELE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SICKLE CELL ANEMIA; T CELL DEPLETION; THALASSEMIA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINOPATHIES; HUMANS; INFANT; MALE; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; TISSUE DISTRIBUTION;

EID: 77958585817     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22739     Document Type: Article

References (43)

1. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225-230.
2. Poonkuzhali B, Chandy M, Srivastava A, et al. Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metab Dispos 2001; 29: 264-267.
3. Grochow LB. Busulfan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20: 18-25, quiz 26.
4. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31-42.
5. Chandy M, Balasubramanian P, Ramachandran SV, et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia-The role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant 2005; 36: 839-845.
6. Poonkuzhali B, Srivastava A, Quernin MH, et al. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 24: 5-11.
7. McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: Cancer incidence and therapy. Oncogene 2006; 25: 1639-1648.
8. Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 2000; 64: 281-291.
9. Gibbs JP, Liacouras CA, Baldassano RN, et al. Up-regulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab Dispos 1999; 27: 1466-1469.
10. Krivoy N, Hoffer E, Lurie Y, et al. Busulfan use in hematopoietic stem cell transplantation: Pharmacology, dose adjustment, safety and efficacy in adults and children. Curr Drug Saf 2008; 3: 60-66.
11. Nguyen L, Leger F, Lennon S, et al. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: A population pharmacokinetic study. Cancer Chemother Pharmacol 2006; 57: 191-198.
12. Goekkurt E, Stoehlmacher J, Stueber C, et al. Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation. Anticancer Res 2007; 27: 4377-4380.
13. DeLeve LD, Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology 2000; 60: 143-154.
14. Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 2000; 61: 154-166.
15. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos 1996; 24: 1015-1019.
16. Srivastava A, Poonkuzhali B, Shaji RV, et al. Glutathione S-transferase M1 polymorphism: A risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004; 104: 1574-1577.
17. Kim I, Keam B, Lee KH, et al. Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Clin Transplant 2007; 21: 207-213.
18. Terakura S, Murata M, Nishida T, et al. Increased risk for treatment-related mortality after bone marrow transplantation in GSTM1-positive recipients. Bone Marrow Transplant 2006; 37: 381-386.
19. McDonald GB, Sharma P, Matthews DE, et al. Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology (Baltimore, MD) 1984; 4: 116-122.
20. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
21. Buchard A, Sanchez JJ, Dalhoff K, et al. Multiplex PCR detection of GSTM1, GSTT1, and GSTP1 gene variants: Simultaneously detecting GSTM1 and GSTT1 gene copy number and the allelic status of the GSTP1 Ile105Val genetic variant. J Mol Diagn 2007; 9: 612-617.
22. Krivoy N, Hoffer E, Tabak A, et al. Therapeutic monitoring of busulfan in pediatric bone marrow transplantation. Pediatr Hematol Oncol 2002; 19: 31-37.
23. Andersson BS, Thall PF, Madden T, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 477-485.
24. Bostrom B, Enockson K, Johnson A, et al. Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation. Pediatr Transplant 2003; 7: 12-18.
25. Takamatsu Y, Ogata K, Yamauchi K, et al. An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Jpn J Clin Oncol 2005; 35: 400-403.
26. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
27. Tozer TN, Hauck WW. Cmax/AUC, a commentary. Pharm Res 1997; 14: 967-968.
28. Endrenyi L, Fritsch S, Yan W. Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence. Int J Clin Pharmacol Ther Toxicol 1991; 29: 394-399.
29. Elhasid R, Krivoy N, Rowe JM, et al. Glutathione S-transferase T1-null seems to be associated with graft failure in hematopoietic SCT. Bone Marrow Transplant advance online publication 29 March 2010; DOI: 10.1038/bmt.2010.61
30. Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 2001; 28: 1013-1018.
31. Nguyen L, Fuller D, Lennon S, et al. I.V. busulfan in pediatrics: A novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant 2004; 33: 979-987.
32. Takama H, Tanaka H, Nakashima D, et al. Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 345-351.
33. Schiltmeyer B, Klingebiel T, Schwab M, et al. Population pharmacokinetics of oral busulfan in children. Cancer Chemother Pharmacol 2003; 52: 209-216.
34. Muller P, Asher N, Heled M, et al. Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups. Leuk Res 2008; 32: 919-929.
35. Ali-Osman F, Akande O, Antoun G, et al. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997; 272: 10004-10012.
36. Coles BF, Morel F, Rauch C, et al. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 2001; 11: 663-669.
37. Bredschneider M, Klein K, Murdter TE, et al. Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: Consequences for enzyme expression and busulfan conjugation. Clin Pharmacol Ther 2002; 71: 479-487.
38. Ansari M, Lauzon-Joset JF, Vachon MF, et al. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. Bone Marrow Transplant 2009.
39. Johnson L, Orchard PJ, Baker KS, et al. Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation. J Clin Pharmacol 2008; 48: 1052-1062.
40. Kusama M, Kubota T, Matsukura Y, et al. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chim Acta Int J Clin Chem 2006; 368: 93-98.
41. Zwaveling J, Press RR, Bredius RG, et al. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. Ther Drug Monit 2008; 30: 504-510.
42. McCune JS, Holmberg LA. Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab Toxicol 2009; 5: 957-969.
43. Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001; 10: 1239-1248.